Eric M. Dube - 01 Apr 2026 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Apr 2026, 17:55:15 UTC
Prior SEC filing
24 Feb 2026
Next SEC filing
15 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

Eric M. Dube filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 02 Apr 2026.

Key facts

  • This page summarizes Eric M. Dube's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 02 Apr 2026, 17:55.

Change

  • Previous filing in this sequence was filed on 24 Feb 2026.
  • Current net transaction value: -$1,855,839.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001763494 Primary reporting owner

Dube Eric M

Relationship
CHIEF EXECUTIVE OFFICER, Director
Address
C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Signature date
02 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Options Exercise

Transaction value
Shares
+60,000
Change %
+14%
Price
$15.46*
Shares after
492,886
Date
01 Apr 2026
Ownership
Direct
TVTX transaction

Common Stock

Sale

Transaction value
$1,066,256
Shares
-34,902
Change %
-7.1%
Price
$30.55
Shares after
457,984
Date
01 Apr 2026
Ownership
Direct
Footnotes
F1, F2
TVTX transaction

Common Stock

Sale

Transaction value
$789,583
Shares
-25,098
Change %
-5.5%
Price
$31.46
Shares after
432,886
Date
01 Apr 2026
Ownership
Direct
Footnotes
F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TVTX transaction Derivative

Employee stock option (right to buy)

Options Exercise

Transaction value
Shares
-60,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
01 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
60,000
Exercise price
$15.46
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.

Footnote F2

The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Footnote F3

The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Footnote F4

The stock option is fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .